{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-034243","form_type":"8-K","ticker":"ATXI","cik":"0001644963","company_name":"AVENUE THERAPEUTICS, INC.","filed_at":"2025-11-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.028493+00:00","generated_at":"2026-05-16T21:15:53.662701+00:00","sec_items":["1.01","5.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"confidence":"high","headline":"Avenue Therapeutics' subsidiary Baergic Bio acquired by Axsome for up to $82M milestones plus royalties","bullets":["Axsome acquires 100% of Baergic Bio equity for $0.3M upfront; development/regulatory milestones up to $2.5M (first indication) and $1.5M per subsequent indication.","Sales-based milestones up to $79M; tiered mid-to-high single digit royalty on global net sales of AXS-17 (formerly BAER-101).","Avenue expects to receive ~74% of all future payments and royalties.","Axsome receives worldwide rights to BAER-101 (GABA A PAM) to be evaluated for epilepsy.","CEO granted 443,578 restricted shares; CFO granted 266,147 restricted shares, fully vesting upon closing."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-034243","json":"https://secwatch.observer/filing/0001437749-25-034243.json","markdown":"https://secwatch.observer/filing/0001437749-25-034243.md","text":"https://secwatch.observer/filing/0001437749-25-034243.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1644963/000143774925034243/0001437749-25-034243-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1644963/000143774925034243/atxi20250430_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T21:15:53.662701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}